Core Insights - The company, China General Nuclear Power Technology (CGN), announced on November 3 that its medical isotope production is a fundamental raw material for the development of nuclear pharmaceuticals, positioning it in the upstream segment of the nuclear medicine industry [2] Group 1 - The core production equipment for the isotope business, including accelerator main devices and process hot rooms, has been delivered and is currently undergoing installation and debugging [2] - The company plans to commence production in 2026 [2]